Progyny, Inc. (NASDAQ:PGNY – Get Free Report) insider Geoffrey Clapp sold 774 shares of the company’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $36.41, for a total value of $28,181.34. Following the transaction, the insider directly owned 58,235 shares of the company’s stock, valued at approximately $2,120,336.35. This represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Progyny Price Performance
Shares of NASDAQ PGNY traded down $0.40 during midday trading on Friday, hitting $36.18. 869,008 shares of the company’s stock were exchanged, compared to its average volume of 1,360,813. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $37.15. The company has a market cap of $2.66 billion, a PE ratio of 33.19, a P/E/G ratio of 1.91 and a beta of 0.97. The firm’s fifty day simple moving average is $28.29 and its 200-day simple moving average is $24.82.
Progyny (NASDAQ:PGNY – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.21. The firm had revenue of $341.25 million during the quarter, compared to analysts’ expectations of $340.76 million. Progyny had a return on equity of 19.82% and a net margin of 6.80%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 earnings per share. Equities analysts anticipate that Progyny, Inc. will post 1.25 EPS for the current fiscal year.
Institutional Investors Weigh In On Progyny
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new stake in shares of Progyny in the second quarter valued at approximately $17,264,000. Hsbc Holdings PLC acquired a new position in shares of Progyny in the 2nd quarter valued at $760,000. AWM Investment Company Inc. acquired a new position in shares of Progyny in the 2nd quarter valued at $6,343,000. Corient Private Wealth LP purchased a new stake in Progyny in the 2nd quarter valued at $3,488,000. Finally, Squarepoint Ops LLC purchased a new stake in Progyny in the 2nd quarter valued at $1,705,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.
Analysts Set New Price Targets
Several analysts have recently weighed in on PGNY shares. Weiss Ratings upgraded shares of Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Leerink Partners upped their target price on shares of Progyny from $37.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Jefferies Financial Group set a $33.00 price objective on Progyny in a report on Tuesday, September 8th. JPMorgan Chase & Co. raised their price objective on Progyny from $30.00 to $35.00 and gave the stock a “neutral” rating in a report on Monday. Finally, Barclays cut their target price on Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 12th. Eleven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and a consensus target price of $35.33.
View Our Latest Report on Progyny
About Progyny
Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.
Featured Articles
- Five stocks we like better than Progyny
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
